Aspirin Inhibits Cell Viability and mTOR Signalling in Neuroendocrine Tumor Cells Abstract #739

Introduction: Patients with multiple endocrine neoplasia (MEN) type 1 develop pancreatic NETs as well as thymic and bronchus carcinoids. Aspirin has been reported to inhibit mTOR signalling and exhibit antitumoral activity in colorectal cancer cells. So far, no data with aspirin on NETs have been published.
Aim(s): To characterize a potential role of aspirin as prophylactic antitumoral drug in MEN-1 patients.
Materials and methods: Human pancreatic neuroendocrine BON1 cells and bronchopulmonary H727 cells were treated with different concentrations of aspirin (0.001mM - 5mM) and the effects on cell viability and various signalling pathways (Western Blot analysis) were examined.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Matilde P Spampatti

To read results and conclusion, please login ...

Further abstracts you may be interested in

#743 In Vitro Anticancer Effect of Metformin on Neuroendocrine Tumor Cells
Introduction: Patients with multiple endocrine neoplasia (MEN) type 1 develop pancreatic NETs as well as bronchus carcinoids. No prophylactic drug is available yet. Metformin has been reported to act on the AMPK/mTOR signalling pathway and exhibit antitumoral activity in several cancer cell lines.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: George Vlotides
#2682 PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNET) remain an unmet clinical need. In this study, we show that targeting both nicotinamide phosphoribosyltransferase (NAMPT) and p21-activated kinase 4 (PAK4) could become a synthetic lethal strategy for PNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Ph.D. Candidate Gabriel Mpilla
Authors: Mpilla G, Aboukameel A, Muqbil I, Kim S, ...
#2694 The Incidence of Gastrointestinal Neuroendocrine Tumors in the Russian Population
Introduction: Over the past four decades, the incidence of neuroendocrine tumors (NETs) has increased. The limited choice of treatments, broad clinical variability of the syndrome explains the increased interest in NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Alina Isiangulova
#2817 METNET: A Phase II Trial of Metformin in Patients with Well Differentiated Neuroendocrine Tumors
Introduction: Preclinical studies have suggested that metformin has antitumor effects, likely due to blockage of mTOR pathway through AMPK and decreased insulin levels. A retrospective study showed that metformin combined with everolimus to treat related hyperglycemia offered longer progression-free survival (PFS) in patients (pts) with pancreatic neuroendocrine tumors (NET).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Prof Rachel Riechelmann
#2876 Efficacy of Surufatinib in Western Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNETs)
Introduction: Surufatinib is a targeted inhibitor of tyrosine kinases VEGFR1, 2, & 3, FGFR1, and CSF-1R. The safety profile was favorable in 2 completed studies (NCT02133157, NCT02267967) conducted in China. A recent phase 3 placebo controlled study (NCT02588170) confirmed safety, and demonstrated superior efficacy (PFS: 9.2 v 3.8 months) of Surufatinib in Chinese pts with advanced extra-pancreatic NETs (epNET).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Medical Writer Kimberly Louis
Authors: Dasari A, Paulson S, Sung M, Tucci C, ...